首页> 外文OA文献 >Percutaneous Management of Thrombosed Dialysis Access Grafts
【2h】

Percutaneous Management of Thrombosed Dialysis Access Grafts

机译:经血栓的透析通路移植物的经皮管理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This article reviews current concepts in the percutaneous management of thrombosed polytetrafluoroethylene (PTFE) dialysis access grafts. The maintenance of dialysis access grafts remains a challenging task. Graft surveillance is critical in the prevention of graft thrombosis to prolong graft survival. Once a graft is thrombosed, surgical and percutaneous options are available for restoration of flow. There has been an evolution in the percutaneous treatment of thrombosed dialysis access grafts during the last 20 years, with refinement of pharmacomechanical techniques, allowing for safe and efficacious restoration of flow in thrombosed grafts. There has been emergence of alternative thrombolytic agents to urokinase, which was withdrawn from the United States in late 1998 and recently reintroduced. These alternative thrombolytic agents have similar outcomes compared with urokinase, with the additional advantage of being less expensive. In addition, several mechanical devices, which were popular briefly when urokinase was unavailable, are available currently for use within grafts, with similar success, although their prices have limited widespread use.
机译:本文回顾了经血栓处理的聚四氟乙烯(PTFE)透析通路移植物的经皮管理的当前概念。维持透析通路移植物仍然是一项艰巨的任务。移植物监测对预防移植物血栓形成以延长移植物存活至关重要。一旦对血栓进行了血栓形成,就可以通过手术和经皮选择恢复血流。在过去的20年中,随着药物机械技术的完善,经血栓的透析通路移植物的经皮治疗有了发展,从而可以安全有效地恢复经血栓的移植物的血流。出现了替代尿激酶的溶栓剂,尿激酶已于1998年底从美国撤出,最近又重新引入。这些替代的溶栓剂与尿激酶相比具有相似的结果,并且具有更便宜的额外优势。此外,目前有几种机械装置在无法使用尿激酶的情况下短暂流行,目前可用于移植物内,但取得了类似的成功,尽管它们的价格限制了其广泛使用。

著录项

  • 作者

    Van Ha, Thuong;

  • 作者单位
  • 年度 2004
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号